Join Dr. Jennie Taylor as she outlines what you need to know about Vorasidenib (VORANIGO®), the latest FDA-approved advancement that targets mutant IDH1 and IDH2 enzymes in the treatment of gliomas. Personal patient reflections will be weaved into the presentation and there will be time for Q&A |
